Change - Announcement of Cessation::Demise of Executive Chairman

Issuer & Securities

Issuer/ Manager
CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED
Securities
CHINA MED (INTL) W201029 - SG5FF2000003 - 1F6W
CHINA MEDICAL (INTL) GROUP LTD - SG1T21929867 - 5IB
CHINA MED (INTL) W180329 - SG9QB8991245 - 5VNW
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Cessation
Date &Time of Broadcast
06-Mar-2018 19:10:23
Status
New
Announcement Sub Title
Demise of Executive Chairman
Announcement Reference
SG180306OTHRC324
Submitted By (Co./ Ind. Name)
Tan Swee Gek
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
The information set out herein in respect of Mr Tai Kok Chuan is to the best of the belief and knowledge of the Company.

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the Sponsor) for compliance with the Singapore Exchange Securities Trading Limited (the SGX-ST) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

Additional Details

Name Of Person
Tai Kok Chuan
Age
61
Is effective date of cessation known?
Yes
If yes, please provide the date
06/03/2018
Detailed Reason (s) for cessation
Mr Tai Kok Chuan passed away on 6 March 2018.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
No
Any other relevant information to be provided to shareholders of the listed issuer?
No
Date of Appointment to current position
18/04/2005
Does the AC have a minimum of 3 members (taking into account this cessation)?
Yes
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
2
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
3
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Chairman
Role and responsibilities
As an Executive Chairman, Mr Tai oversaw the formulation of policies, growth strategies and the overall management of the Group.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
None.
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Direct Interest
440,000,000 shares;
75,714,000 options; and
330,000,000 warrants

Deemed Interest
80,000,000 shares; and
60,000,000 warrants.
Past (for the last 5 years)
TQAQI International Pte. Ltd.
Present
Arion Entertainment Singapore Ltd
Albedo Corporation Pte. Ltd.
Albedo Sdn. Bhd.
China iMyth Company Pte. Ltd.
iMyth Taiwan Limited
China iMyth (Hong Kong) Pte. Ltd.
China iMyth (Shanghai) Co., Ltd.
CMIC Hemodialysis Pte. Ltd.
CMIC Hemodialysis (Hong Kong) Limited